Longer-term cardiac safety and outcomes of dose dense (dd) doxorubicin and cyclophosphamide (AC) followed by paclitaxel (T) and trastuzumab (H) with and without lapatinib (L) in patients (pts) with ...

Severe hypothyroidism is associated with a high burden of systolic/diastolic ventricular dysfunction and myocardial deformation abnormalities.

Whether revascularization by percutaneous coronary intervention (PCI) can improve event-free survival and left ventricular function in patients with severe ischemic left ventricular systolic ...

Left ventricular noncompaction is characterized by deep trabeculations in the LV endocardium in association with left ventricular hypertrophy, dilation or hypertrophy/dilation. Noncompaction of the ...

Demographic, systemic sclerosis (SSc)-specific, and cardiac factors raised the risk for left ventricular systolic dysfunction (LVSD) in a study of patients with SSc. Researchers used the Johns Hopkins ...

Please provide your email address to receive an email when new articles are posted on . HF and LV dysfunction affect about 9% of adults aged 60 years and older, and there are effective treatments to ...

Percutaneous coronary intervention (PCI) does not reduce all-cause mortality or heart failure hospitalization in patients with severe left ventricular dysfunction and extensive coronary artery disease ...

Left ventricular hypertrophy (LVH) is when the heart’s main pumping chamber, the left ventricle, becomes thicker and less able to pump blood efficiently. It usually develops because of another heart ...